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SUMMARY
Vulvovaginal candidiasis (VVC) in HIV-infected women contributed to the impairment of their quality of life. The aim of this 
study was to evaluate the effect of highly active antiretroviral therapy (HAART) use on the vaginal Candida spp. isolation in HIV-
infected compared to HIV-uninfected women. This cross-sectional study included 178 HIV-infected (HIV group) and 200 HIV-
uninfected women (control) that were studied at the Specialized Assistance Service (SAE) for sexually transmitted diseases (STD)/
AIDS of the city of Maringá, Brazil, from April 1 to October 30, 2011. The yeasts were isolated and identified by phenotypic and 
molecular methods. The in vitro antifungal susceptibility to fluconazole, itraconazole, nystatin and amphotericin B was tested by the 
reference microdilution method. Higher frequencies of total vaginal Candida spp. isolation were found in the HIV-infected group 
than in the control group. However, both groups showed a similar frequency of colonization and VVC. Although C. albicans was 
the most frequent and sensitive to azolics and polyenes in both HIV-infected and uninfected women, the emerging resistance of C. 
glabrata to amphotericin B in the HIV-infected women was observed. Although higher frequency of vaginal Candida spp. isolation 
had been observed in the HIV-infected than in HIV-uninfected women, colonization and VVC showed similar frequency in both 
groups, indicating that HAART appears to protect against vaginal colonization and VVC.
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INTRODUCTION
Vulvovaginal candidiasis (VVC) is a disease caused by the abnormal 
growth of yeast-like fungi in the mucosa of the female genital tract by 
members of the genus Candida21. These yeasts, in particular C. albicans, 
are well adapted to the human body, and are capable of colonizing 
it without producing signs of disease in conditions of physiological 
equilibrium28. However, under conditions that disrupt the delicate balance 
between the host and this commensal fungus, a parasitic relationship may 
occur, resulting in the development of infections termed candidiasis, 
including VVC2. For development of VVC, predisposing factors related 
to the host are very important, mainly being immunosuppressive diseases, 
such as HIV infection13,15.
Because it strikes millions of women annually, causing great 
discomfort, interfering with sexual and affective relations and impairing 
work performance, VVC has been considered an important worldwide 
public-health problem5,24. In HIV-infected women, the impact of VVC 
on top of other medical complications that stem from the viral infection 
and its treatment certainly contributes to the impairment of their quality 
of life. It must still be considered that out of HIV-infected individuals 
worldwide (around 40 million), nearly half are women16, raising concerns 
about VVC. In Brazil, HIV infection occurs in 0.5% of the population, 
with a trend toward expansion of the epidemic among women, from a 
ratio of 18.5 men:1 woman in the 1980s to 1.5:1 in 20042.
Use of the highly active antiretroviral therapy (HAART) has extended 
the life span of HIV-infected persons. However, some studies have 
reported that even for users of this continuous therapy opportunistic 
infections remain a serious problem3,18. Nevertheless, to the authors’ 
knowledge, few studies have related vaginal Candida colonization and 
VVC in HIV-infected women to HAART use in different populations, 
have enrolled relatively few HIV-infected women15, only treated specific 
clinical conditions as Candida colonization14, lacked appropriate matched 
controls9,15, or have been restricted to specialized subpopulations such 
as women with symptoms of vulvovaginitis23. There are some available 
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studies that were performed before the broad use of HAART or in 
populations that do not regularly use this therapy1,7,9,23,27. 
The aim of this study was to evaluate the effect of HAART use on the 
vaginal Candida spp. isolation in two clinical conditions: colonization and 
VVC, in HIV-infected compared to HIV-uninfected women. In addition, 
the antifungal susceptibility of Candida species to the most commonly 
used antifungal drugs was evaluated.
MATERIAL AND METHODS
This was a cross-sectional study that included a group of 178 
HIV-infected and 200 HIV-uninfected women, who were studied at the 
Specialized Assistance Service (SAE) for sexually transmitted diseases 
(STD)/AIDS in the city of Maringá, Brazil, from April 1 to October 
30, 2011. Inclusion criteria were women having diagnoses of HIV/
AIDS confirmed by two different methods (HIV group), or confirmed 
diagnosis as HIV-uninfected (control group). Exclusion criteria were: 
hysterectomized women, pregnant or postpartum women, women of 
less than 18 years of age, women with no history of sexual activity, 
women that had some degree of difficulty in understanding the study, 
women suffering vaginal bleeding, or women that had undergone sexual 
intercourse/vaginal douching within the 48 hours preceding collection 
of the vaginal sample.
The women signed the consent form to participate in the study, 
and completed a standardized questionnaire with information 
regarding symptoms of VVC. The HIV group also responded to a 
questionnaire regarding socio-demographic characteristics, obstetrical 
and gynecological history, and sexual behavior. Data regarding HIV 
infection, including the period of infection (years), CD4+ T lymphocyte 
count, HIV viral load values, and HAART use were obtained from 
the medical records of each woman. A single health professional was 
responsible for contacting the women, administering the questionnaire, 
and collecting the vaginal sample. This research was approved by 
the Committee for Ethics in Research Involving Humans at the State 
University of Maringá, Paraná, Brazil (reports No. 185/2007 and No. 
085/2011). 
Vaginal samples were collected with sterile swabs and a disposable 
vaginal speculum, inoculated in sterile saline, and immediately seeded 
onto plates containing Sabouraud dextrose agar (SDA) (Difco, USA), 
with the addition of 100 mg/mL chloramphenicol, and incubated at 
25 °C for up to five days. A pool of the colonies grown on each plate was 
subcultured on CHROMágar Candida (Probac, France) to assure the 
purity of the isolates and to identify mixed cultures. Beginning with the 
pure culture, the yeasts were identified by classical phenotypic methods11. 
Additionally, the identification of yeasts was confirmed using matrix-
assisted laser-desorption/ionization time-of-flight mass spectroscopy 
assay (MALDI TOF-MS). For MALDI TOF-MS identification, yeasts 
were prepared26 and the measurements were performed19 with Microflex 
LT mass spectrometer (Bruker Daltonics, Germany) using FlexControl 
software (version 3.0, Bruker Daltonics, Germany). The yeasts were 
stored in Sabouraud dextrose broth (SDB) (Difco, USA) with 10% 
glycerol at -20 °C. 
Women were evaluated for the presence of clinical signs and 
symptoms of VVC by SAE doctors. Candida vaginal colonization was 
defined as culture positive for yeasts from women without signs and 
symptoms of VVC. Women with a positive culture were considered 
to have VVC if they reported at least two symptoms of this pathology 
(discharge, burning, vaginal itching, dysuria or dyspareunia), and signs 
of VVC reported by doctors12.
The in vitro antifungal activity assay was performed for fluconazole 
(FLU, Pfizer Inc., NY, USA), itraconazole (ITRA, Janssen Pharmaceutical, 
NJ, USA), nystatin (NYST, Sigma Pharma, MO, USA) and Amphotericin 
B (AMB, Squibb Pharmaceutical, NJ, USA). All yeasts isolated were 
tested by means of the Clinical Laboratory Standards Institute reference 
broth microdilution method for fluconazol and itraconazol, with 
modifications for other drugs4,5. The minimum inhibitory concentration 
(MIC) for azoles was defined as the first well with a significant growth 
reduction (approximately 50%) compared to that of the positive control. 
In the case of NYST and AMB, the MIC was defined as the lowest 
concentration capable of inhibiting 90% of the growth17. The endpoints 
for antifungal agents: isolates with MIC between 16 and 32 µg/mL for 
FLU, 0.25 to 0.5 µg/mL for ITRA, and 8 to 32 µg/mL for NYST were 
considered as dose-dependent susceptibility (DDS). Isolates with an MIC 
≤ 8 µg/mL for FLU, ≤ 0.125 µg/mL for ITRA, ≤ 4 µg/mL for NYST, 
and ≤ 1 µg/mL for AMB were susceptible (S). Those with an MIC ≥ 64 
µg/mL for FLU, ≥ 1 µg/mL for ITRA, ≥ 64 µg/mL for NYST and ≥ 2 
µg/mL for AMB were resistant (R). 
The statistical analysis was performed using the STATA for Statistics 
and Data Analysis 9.1 software. All variables were expressed as absolute 
and relative frequencies. The frequencies of Candida spp. isolation from 
the vaginal mucosa, and also colonization and VVC, were calculated 
by the crude odds ratio (OR) with a 95% confidence interval (CI), and 
were evaluated between groups by the Chi-square test (χ²) with Yates 
correction. A value of p < 0.05 was considered significant. 
RESULTS
Figure 1 is an overview of the study and results.
Table 1 describes the socio-demographic and clinical characteristics 
of the two groups. The median age of the HIV group was 41.24 ± 10.31 
years, and for the control group it was 42.22 ± 14.14 years (p > 0.05). 
Considering all women studied, Candida spp. isolation from the vaginal 
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Table 1
Relationship between total Candida vaginal isolation, colonization and VCC, as well as the socio-demographic characteristics, obstetrical and  
gynecological history, sexual behavior and data regarding HIV of 178 HIV-infected women














n  (%) n  (%) n  (%) n  ( %)
Age (years)
15 to 30 28 15.7 10 27.8 0.4206 4 21.1 0.7867 6 35.3 0.2861
31 to 40 60 33.7 17 47.2 0.0286* 7 36.8 0.2285 10 58.8 0.0131*
≥  41 90 50.6 9 25.0 0.1400 8 42.1 0.646 1 5.9 0.2103
Marital status
married/cohabiting 93 52.2 19 52.8 0.9494 7 36.8 0.4337 12 70.6 0.2264
unmarried/non-cohabiting 85 47.8 17 47.2 0.9521 12 63.2 0.3204 5 29.4 0.4202
Education
< 8 years 85 47.8 12 33.3 0.3414 5 26.3 0.3515 7 41.2 0.7375
≥ 8 years 93 52.2 24 66.7 0.1994 14 73.7 0.8782 10 58.8 0.6832
Family income
< $ 240/month 25 14.0 4 11.1 0.8763 2 10.5 0.8911 2 11.8 0.9316
≥ $ 240/month 153 86.0 32 88.9 0.6519 17 89.5 0.6906 15 88.2 0.8139
Skin color
white 109 61.2 18 50.0 0.3803 11 57.9 0.8311 7 41.2 0.3025
brown 50 28.1 12 33.3 0.7177 6 31.6 0.8582 6 35.3 0.7105
black 15 8.4 6 16.7 0.5635 2 10.5 0.9222 4 23.5 0.3957
yellow 4 2.2 0 0.0 - 0 0.0 - 0 0     -
Employ out side the home
yes 98 55.1 23 63.9 0.4397 13 68.4 0.3652 10 58.9 0.8136
No 80 44.9 13 36.1 0.5500 6 31.6 0.5254 7 41.1 0.8467
Age of first sexual  intercourse
< 18 112 62.9 24 66.7 0.7329 15 78.9 0.2254 9 53.0 0.5527
≥ 18 66 37.1 12 33.3 0.8071 4 21.1 0.5201 8 47.0 0.584
Number of lifetime sexual partners
< 10 129 72.5 25 69.4 0.7923 14 73.7 0.953 11 64.8 0.6127
≥ 10 49 27.5 11 30.6 0.8635 5 26.3 0.9545 6 35.2 0.7146
Number of deliveries
< 3 87 48.9 17 47.2 0.8922 8 42.1 0.7135 9 53.0 0.8198
≥ 3 91 51.1 19 52.8 - 11 57.9 0.6708 8 47.0 0.8287
Period of  HIV infection (years)
< 10 131 73.6 25 69.4 0.6346 15 78.9 0.6576 10 58.9 0.3021
≥ 10 47 26.4 11 30.6 0.7579 4 21.1 0.8175 7 41.1 0.4101
HAART use
yes 141 79.2 22 61.1 0.0670 13 68.4 0.3676 9 53.0 0.0724
no 37 20.8 14 38.9 0.1990 6 31.6 0.5588 8 47.0 0.1340
Current  CD4+ T lymphocyte count
< 200  cells/mm3 15 8.4 6 16.7 0.5635 2 10.5 0.9222 4 23.5 0.3957
200 and 350  cells/mm3 32 18.0 8 22.2 0.7873 5 26.3 0.6634 3 17.6 0.9863
> 350  cells/mm3 131 73.6 22 61.1 0.2136 12 63.2 0.4401 10 58.9 0.3021
Current viral load
< minimum limit copies/ml 104 58.4 11 30.6 0.0848 6 31.6 0.2001 5 29.4 0.2039
Minimum limit - 100,000 copies/mL 69 38.8 22 61.1 0.0726 11 57.9 0.2360 11 64.7 0.1134
> 100,000 copies/mL 5 2.8 3 8.3 0.7502 2 10.5 0.6904 1 5.9 0.8637
VVC, vulvovaginal candidiasis;*p < 0.05 was considered significant.
ALCZUK, S.S.D.; BONFIM-MENDONÇA, P.S.; ROCHA-BRISCHILIARI, S.C.; SHINOBU-MESQUITA, C.S.; MARTINS, H.P.R.; GIMENES, F.; ABREU, A.L.P.; CARVALHO, M.D.B.; 
PELLOSO, S.M.; SVIDZINSKI, T.I.E. & CONSOLARO, M.E.L. - Effect of highly active antiretroviral therapy on vaginal Candida spp. isolation in HIV-infected compared to HIV-
uninfected women. Rev. Inst. Med. Trop. Sao Paulo, 57(2): 169-74, 2015.
172
mucosa and VVC was significantly associated with the 31 to 40 years 
of age group (p = 0.0286 and p = 0.0131, respectively). For the groups 
studied, only the control group showed association with age, since vaginal 
yeast colonization was significantly associated with the 31 to 40 years 
of age group (p = 0.0185). Data regarding HIV infection, including the 
period of HIV infection, CD4+ T lymphocyte count, HIV viral load 
values and correct use of HAART were not significantly associated with 
Candida spp. total isolation, colonization or VVC.
The HIV infected group showed a higher frequency of colonization 
than VVC (52.8% and 47.2%, respectively, p = 0.05), and the control 
group showed more frequent VVC than colonization (55.5% and 44.4%, 
respectively; p = 0.01). However, comparing the two groups, Candida 
spp. total vaginal isolation was more frequent in the HIV group (n = 
36/178, 20.2%) than in the control group (18/200, 9.0%; p = 0.003). 
For clinical conditions, the HIV group showed a similar frequency of 
vaginal colonization (19/178, 10.7%) (OR = 2.9; 95% CI 0.91-9.6; p = 
0.1072) and VVC (17/178, 9.5%) (OR = 1.879; 95% CI 0.8657-1.994; 
p = 0.4057) to the control group (n = 8/200, 4.0%; n = 10/200, 5.0%, 
respectively) (Table 2). 
With respect to yeast species in the present study, C. albicans was the 
most frequently isolated in both the HIV (n = 26, 72.2%; p = 0.02) and 
control groups (n = 10, 55.6%; p = 0.05). With respect to yeast species 
in different clinical conditions, the HIV group showed more C. albicans 
than the control in VVC (p = 0.007; OR 3.1; 95% CI 1.24-9.05) and in 
colonization (p = 0.005; OR 2.9; 95% CI 0.91-10.87). In the HIV group, 
the following non-albicans species were identified: C. glabrata (n = 7), 
C. parapsilosis (n = 2) and C. rugosa (n = 1). In the control group, the 
following were identified: C. glabrata (n = 5), C. parapsilosis (n = 2) and 
C. tropicalis (n = 1). Thus, in both groups, C. glabrata was the second 
most common yeast isolated (19.4% and 27.8%, for the HIV and control 
groups, respectively) (Table 2). 
Table 3 shows the interpretation of the antifungal activity results 
for drugs as well as for susceptibility, dose-dependent susceptibility or 
resistance. In general, the C. albicans isolates showed no resistance to 
the antifungal agents tested for both the HIV and the control group. The 
results for amphotericin B were 100% sensitivity. For nystatin, the results 
showed elevated rates of vaginal isolates of C. albicans and non-albicans 
species with dose-dependent susceptibility. Of the non-albicans species 
identified in the HIV group, only C. glabrata showed resistance, one 
(4.8%) to FLU, two (9.5%) to ITRA, and another two (9.5%) to AMB. 
In the control group, two non-albicans yeasts (23.3%) showed resistance 
to FLU and one (6.7%) to ITRA; the two resistant species found in this 
group were C. glabrata and C. tropicalis. 
DISCUSSION
In the present study, Candida spp. total vaginal isolation was 
significantly more frequent in the HIV group than in the control group. 
However, a similar frequency of colonization and VVC in the HIV and 
Table 2
Frequencies of Candida spp. vaginal total isolation, colonization and vulvovaginal candidiasis (VVC) in HIV-infected and uninfected women in southern Brazil
Candida species
HIV-infected group 
 n = 178
HIV-uninfected group 
n = 200
Total isolation Colonization VVC Total isolation Colonization VVC
n % n % n % n % n % n %
C. albicans 26 72.2 10  52.6 16 94.1 10 55.6 4 50.0 6 60.0
Non-albicans species 10 27.8 9  47.4 1 5.9 8 44.4 4 50.0 4 40.0
Total 36 100.0 19 52.7 17 47.3 18 100.0 8 44.4 10 55.5
Table 3
Interpretation of the results for minimal inhibitory concentration (MIC) for antifungal drugs in vaginal yeasts from HIV-infected (n = 36, C. albicans = 26) and HIV-
uninfected groups (n = 18, C. albicans = 10)
Antifungals
HIV-infected group HIV-uninfected group
C. albicans non-albicans species C. albicans non-albicans species
S DDS R S DDS R S DDS R S DDS R
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
FLU 24 92.3 2 7.7 - - 4 71.4 5 23.8 1 4.8 10 100.0 - - - - 1 33.3 5 43.4 2 23.3
ITRA 25 96.1 1 3.9 - - 8 90.5 - - 2 9.5 9 90.0 1 10.0 - - - - 7 93.3 1 6.7
NYST 25 96.1 1 3.9 - - 8 66.7 2 33.3 - - 3 30.0 7 70.0 - - 6 76.7 2 23.3 - -
AMB 26 100.0 - - - - 8 90.5 - - 2 9.5 10 100.0 - - - - 8 100.0 - - - -
FLU = fluconazole; ITRA = itraconazole; NYST = nistatyn and AMB = amphotericn B; S (susceptible): isolates with MICs ≤ 8 µg/mL for FLU; ≤ 0.125 µg/mL for ITRA; ≤ 4 µg/mL for NYST; 
≤ 1 µg/mL for AMB. DDS (dose-dependent susceptibility): isolates with MIC between 16 and 32 µg/mL for FLU; ≤ 0.25 to 0.5 µg/mL for ITRA; ≤ 8 to 32 µg/mL for NYST. R (resistant): 
Isolates with MIC ≥ 64 µg/mL for FLU; ≥ 1 µg/mL for ITRA; ≥ 64 µg/mL for NYST; ≥ 2 µg/mL for AMB.
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control groups was shown, which is consistent with the results of the 
most HIV-infected women enrolled in this study that showed excellent 
control of the infection. Further, the data regarding HIV infection were 
not associated with Candida spp. isolation from the vaginal mucosa, 
colonization or VVC. 
The results found in this study differ from those described in other 
populations that also had good control of HIV infection. In these studies, 
the frequency of VVC in the HIV group was similar to the control group, 
but the frequency of colonization was higher7,15. Also, for vaginal Candida 
colonization, the results differ from those in which the risk of colonization 
in HIV-infected women with CD4+ T-cell counts below 100-200 cells/
mm3 was three or four times higher, compared to immunocompetent 
HIV-infected or HIV-uninfected women1,7. 
The results are encouraging, since HAART seems to protect against 
vaginal colonization and VVC, and some investigators have reported 
a relationship between vaginal Candida colonization and VVC with 
heterosexual transmission of HIV. Recent research has shown that 
women with vaginal yeasts were more likely to acquire HIV, and the 
condition may contribute more to the HIV epidemic than previously 
thought27. It was shown that treatment of VVC in HIV-infected women 
can reduce genital shedding of HIV RNA and DNA by 3.2 and 3 times, 
respectively17.
For the HIV and control groups, C. glabrata was the second most 
common yeast isolated, in agreement with other studies1,15. Older studies 
described higher rates of vaginal colonization with non-albicans species 
in HIV-infected than in uninfected women7,17. With respect to yeast 
species in different clinical conditions, the HIV group showed more C. 
albicans than the control group in VVC and in colonization, similar to 
other studies1. In some studies, C. albicans was related to symptoms in 
HIV-infected women22, but in others no relationship between symptoms 
and the yeast species isolated15 was found.
In relation to antifungal susceptibility, C. albicans showed no 
resistance to the antifungal agents tested for both the HIV and the 
control group and 100% of sensibility for amphotericin B. These results 
reinforce previous findings showing that amphotericin B is an excellent 
and highly efficacious therapeutic option for vaginal C. albicans including 
in HIV-infected women8. For nystatin, the results of this study are in 
accordance with others that have shown elevated rates of vaginal isolates 
with dose-dependent susceptibility, and also some resistance5. Nystatin 
has been used for several decades as one of the principal treatments for 
vaginal Candida spp. in Brazil23. This history may partly explain the 
elevated dose-dependent susceptibility rate observed in both groups 
studied. Large-scale use of fluconazole began more recently, which may 
also partly explain the better therapeutic activity of this drug against C. 
albicans found in the present study. 
Non-albicans species showed resistance to fluconazole and 
itraconazole. In general, these results are not surprising since the 
management of women with non-albicans species, mainly C. glabrata, 
is difficult because of the lower sensitivity of non-albicans species to 
both azoles6,25 and polyenes10. To the authors’ knowledge, this is one of 
the first studies to show amphotericin B resistance in C. glabrata isolated 
from HIV-infected women. The importance of the results in relation to 
antifungal susceptibility is confirmed by the report which found no trials 
that addressed treatment of VVC in HIV-infected women20. However, 
there is a need to evaluate drugs and drug regimens for VVC treatment 
and prophylaxis in HIV-infected women. 
In conclusion, this study found higher frequencies of total vaginal 
Candida spp. isolation in the HIV-infected women with prolonged 
HAART use, in relation to HIV-uninfected. However, a similar frequency 
of colonization and VVC in the HIV and control groups was shown. Thus, 
the results are encouraging, since HAART seems to protect against vaginal 
colonization and VVC. Although C. albicans was the most frequent and 
sensitive to azolics and polyenes in both HIV-infected and uninfected 
women, the emerging resistance of C. glabrata to amphotericin B in the 
HIV-infected women studied was observed. If this proves to be correct, 
implementing routine culture identifications of vaginal Candida spp. in 
HIV-infected women could help in guiding treatment, assisting in care, 
and improving the quality of life of these patients. Once the resistance of 
C. glabrata to amphotericin B is detected, and this yeast is intrinsically 
resistant to azoles, it is important to have knowledge of their involvement 
in VVC of HIV-positive women. 
RESUMO
Efeito da terapia anti-retroviral altamente ativa no isolamento 
vaginal de Candida spp. em mulheres infectadas por HIV 
comparado às não infectadas
Candidíase vulvovaginal (CVV) em mulheres infectadas pelo 
HIV contribuiu substancialmente para a diminuição da sua qualidade 
de vida. O objetivo deste estudo foi avaliar o efeito do uso de terapia 
anti-retroviral altamente ativa (HAART) no isolamento de Candida 
spp. vaginais em mulheres HIV positivas comparado às não infectadas 
por HIV. Este estudo transversal incluiu 178 mulheres infectadas pelo 
HIV (grupo HIV) e 200 mulheres não infectadas (grupo controle) 
acompanhadas no Serviço de Assistência Especializada (SAE) para 
as doenças sexualmente transmissíveis (DST)/AIDS da cidade de 
Maringá/Brasil, de 1 abril a 30 de outubro de 2011. As leveduras 
foram isoladas e identificadas por métodos fenotípicos e moleculares. 
A susceptibilidade in vitro aos antifúngicos fluconazol, itraconazol, 
nistatina e anfotericina B foi avaliada pelo método de referência de 
microdiluição. Nós encontramos maior frequência de isolamento 
vaginal total de Candida spp. no grupo HIV do que no grupo controle. 
Entretanto, foi observada frequência similar de colonização e CVV entre 
os dois grupos. Apesar de C. albicans ser a mais frequente e sensível a 
azólicos e polienos em mulheres infectadas pelo HIV e não infectadas, 
foi detectada emergente resistência de C. glabrata a AMB nas mulheres 
infectadas pelo HIV. Embora tenha sido observada maior frequência de 
isolamento vaginal de Candida spp. nas mulheres infectadas pelo HIV 
do que nas não infectadas, colonização e CVV apresentaram frequência 
similar em ambos os grupos, o que indica que HAART parece proteger 
contra colonização vaginal e CVV.
ACKNOWLEDGMENTS
This study was supported by grants from the Fundação Araucária 
Apoio ao Desenvolvimento Científico e Tecnológico do Paraná, the 
Ministério da Saúde do Brasil, (Grant number EFP 00002873-SISCT) and 
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, 
AUX-PE-PRODOC 2571/2010), Brazilian Government.
ALCZUK, S.S.D.; BONFIM-MENDONÇA, P.S.; ROCHA-BRISCHILIARI, S.C.; SHINOBU-MESQUITA, C.S.; MARTINS, H.P.R.; GIMENES, F.; ABREU, A.L.P.; CARVALHO, M.D.B.; 
PELLOSO, S.M.; SVIDZINSKI, T.I.E. & CONSOLARO, M.E.L. - Effect of highly active antiretroviral therapy on vaginal Candida spp. isolation in HIV-infected compared to HIV-
uninfected women. Rev. Inst. Med. Trop. Sao Paulo, 57(2): 169-74, 2015.
174
AUTHOR DISCLOSURE STATEMENT
No competing financial interests exist.
REFERENCES
 1.  Beltrame A, Matteelli A, Carvalho AC, Saleri N, Casalini C, Capone S, et al. Vaginal 
colonization with Candida spp. in human immunodeficiency virus-infected women: 
a cohort study. Int J STD AIDS. 2006;17:260-6. doi:10.1258/095646206776253435.
 2.  Brasil. Ministério da Saúde. AIDS Boletim Epidemiológico julho - dezembro 2010/
janeiro - julho 2012. Bol Epidemiol Aids. 2012;8:9-79.
 3.  Centers for Disease Control and Prevention. Guidelines for prevention and treatment 
of opportunistic infections among HIV-exposed and HIV-infected children. MMWR. 
2009;58(RR-04):1-198. [cited 2009 Sep 15]. Available from: http://www.cdc.gov. 
 4.  Clinical and Laboratory Standards Institute. Reference method for broth dilution 
antifungal susceptibility testing for yeasts. 3rd ed. Wayne: CLSI; 2008. (CLSI 
M27-A3).
 5.  Dalben-Dota KF, Faria MG, Bruschi ML, Pelloso SM, Lopes-Consolaro ME, 
Svidzinski TI. Antifungal activity of propolis extract against yeasts isolated from 
vaginal exudates. J Altern Complement Med. 2010;16:285-90. doi:10.1089/
acm.2009.0281.
 6.  Dota KFD, Shinobu CS, Patussi EV, Consolaro MEL, Svidzinski TIE. Susceptibility 
to vaginal yeast in most used antifungal in Maringá, Paraná, Brazil. Acta Bioquim 
Clin Latinoam. 2008;110:66-72. 
 7.  Duerr A, Heilig CM, Meikle SF, Cu-Uvin S, Klein RS, Rompalo A, et al. Incident and 
persistent vulvovaginal candidiasis among human immunodeficiency virus-infected 
women: risk factors and severity. Obstet Gynecol. 2003;101:548-56. 
 8.  Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of 
resistance, and correlation of these mechanisms with bacterial resistance. Clin 
Microbiol Rev. 1999;12:501-17. 
 9.  Grinsztejn B, Bastos FI, Veloso VG, Friedman RK, Pilotto JH, Schechter M, 
et al. Assessing sexually transmitted infections in a cohort of women living 
with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS. 2006;17:473-8. 
doi:10.1258/095646206777689071.
 10.  Holland J, Young ML, Lee O, C-A Chen S. Vulvovaginal carriage of yeasts other 
than Candida albicans. Sex Transm Infect. 2003;79:249-50. 
 11.  Kurtzman C, Fell JW, Boekhout T. The yeasts: a taxonomic study. 4th ed. Amsterdam: 
Elsevier: 1998.
 12.  Lopes Consolaro ME, Aline Albertoni T, Shizue Yoshida C, Mazucheli J, Peralta 
RM, Estivalet Svidzinski TI. Correlation of Candida species and symptoms among 
patients with vulvovaginal candidiasis in Maringa, Parana, Brazil. Rev Iberoam Micol. 
2004;21:202-5. 
 13.  Martins HP, da Silva MC, Paiva LC, Svidzinski TI, Consolaro ME. Efficacy of 
fluconazole and nystatin in the treatment of vaginal Candida species. Acta Derm 
Venereol. 2012;92:78-82. doi:10.2340/00015555-1194.
 14.  Merenstein D, Hu H, Wang C, Hamilton P, Blackmon M, Chen H, et al. Colonization 
by Candida species of the oral and vaginal mucosa in HIV-infected and noninfected 
women. AIDS Res Hum Retroviruses. 2013;29:30-4. doi:10.1089/aid.2012.0269.
 15.  Moragues MD, Omaetxebarria MJ, Elguezabal N, Sevilla MJ, Conti S, Polonelli L, et. 
al. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein 
exerts three anti-C. albicans activities. Infect Immun. 2003;71:5273-9. 
 16.  Mumtaz G, Hilmi N, Akala FA, Semini I, Riedner G, Wilson D, et al. HIV-1 molecular 
epidemiology evidence and transmission patterns in the Middle East and North Africa. 
Sex Transm Infect. 2011;87:101-6. doi:10.1136/sti.2010.043711.
 17.  Nardin ME, Morano S, Ahumada C, Volta G, Fernandez S, Méndez E. Prevalence of 
the vulvovaginal candidosis and its relationship with some risk factors. Rev Argent 
Micol. 2000;22:13-9. 
 18.  Oliveira PM, Mascarenhas RE, Lacroix C, Ferrer SR, Oliveira RP, Cravo EA, et 
al. Candida species isolated from the vaginal mucosa of HIV-infected women in 
Salvador, Bahia, Brazil. Braz J Infect Dis. 2011;15:239-44.
 19.  Pascon RC, Bergamo RF, Spinelli RX, de Souza ED, Assis DM, Juliano L, et al. 
Amylolytic microorganism from São Paulo zoo composting: isolation, identification, 
and amylase production. Enzyme Res. 2011:679624. doi:10.4061/2011/679624.
 20.  Ray A, Ray S, George AT, Swaminathan N. Interventions for prevention and treatment 
of vulvovaginal candidiasis in women with HIV infection. Cochrane Database Syst 
Rev. 2011(8):Cd008739. doi:10.1002/14651858.CD008739.pub2
 21.  Reese RE, Betts RF. Antibiotic use. In: Reese RE, Betts RF. A practical approach to 
infectious diseases. 3rd ed. Boston: Little, Brown and Company; 1991.
 22.  Ribeiro MA, Miranda AE, Gambale W, Paula CR. Prevalence and exoenzyme secretion 
by Candida albicans isolates from oral and vaginal mucosas of HIV-infected women. 
Mycopathologia. 2004;157:255-61. 
 23.  Ribeiro MA, Paula CR, John R, Perfect JR, Cox GM. Phenotypic and genotypic 
evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-
infected women from Brazil. Med Mycol. 2005;43:647-50. 
 24.  Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-71.
 25.  Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal 
candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet 
Gynecol. 1998;178:203-11. 
 26.  Spanu T, Posteraro B, Fiori B, D’Inzeo T, Campoli S, Ruggeri A, et al. Direct 
maldi-tof mass spectrometry assay of blood culture broths for rapid identification of 
Candida species causing bloodstream infections: an observational study in two large 
microbiology laboratories. J Clin Microbiol. 2012;50:176-9. doi:10.1128/jcm.05742-
11.
 27.  van de Wijgert JH, Morrison CS, Cornelisse PG, Munjoma M, Moncada J, Awio P, 
et al. Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-
1 acquisition in African women. J Acquir Immune Defic Syndr. 2008;48:203-10. 
doi:10.1097/QAI.0b013e3181743936.
 28.  Wei YP, Feng J, Luo ZC. Isolation and genotyping of vaginal non-albicans Candida 
spp. in women from two different ethnic groups in Lanzhou, China. Int J Gynaecol 
Obstet. 2010;110:227-30. doi:10.1016/j.ijgo.2010.04.026.
Received: 24 March 2014
Accepted: 7 July 2014
